7 completed, 4 unknown, 1 withdrawn. 12 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 7, Unknown 4, Withdrawn 1 |
| Phase 2 | 6 | Unknown 4, Completed 2 |
Follow Deferiprone: new trials by email Literature Review of Deferiprone trials Research Report on Deferiprone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Deferiprone, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | University Hospital, Lille | 372 | 2019-01-30 | 2025-12-05 |
| Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy Deferiprone, Acetylcysteine, Sitagliptin and Metformin - Diabetes Mellitus, Iron Metabolism Disorders | Phase 2 / Phase 3 | Unknown | Hadassah Medical Organization | 20 | 2016-12-01 | 2016-08-29 |
| An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Deferiprone - Beta Thalassemia Major | Phase 2 / Phase 3 | Unknown | Ain Shams University | 64 | 2014-07-01 | 2015-01-14 |
| Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration Deferiprone oral solution - Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | Completed | ApoPharma | 68 | 2014-06-01 | 2020-08-25 |
| Role of Vitamin C to Augment Iron Chelation With DFP or DFX Vitamin C, Defriprone, deferisarox, deferiprone , deferesarox - Vitamin c, Thalassemia Major | Phase 2 / Phase 3 | Unknown | Ain Shams University | 50 | 2014-04-01 | 2014-03-11 |
| Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients Deferiprone, Deferasirox - Chronic Iron Overload | Phase 3 | Completed | Consorzio per Valutazioni Biologiche e Farmacologiche | 435 | 2014-03-17 | 2021-05-04 |
| Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) Deferiprone oral solution, Placebo - Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | Completed | ApoPharma | 89 | 2012-12-13 | 2019-07-05 |
| Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload DFP (ferriprox) and deferasirox (ICL 670), DFP, DFO - Beta-thalassemia Major, Sickle Cell Disease | Phase 2 / Phase 3 | Unknown | Ain Shams University | 60 | 2012-02-01 | 2012-02-06 |
| Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent deferiprone, Placebo - Acute Kidney Injury | Phase 3 | Withdrawn | CorMedix Therapeutics | 2012-01-01 | 2020-08-24 | |
| Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease deferiprone, placebo - Parkinson's Disease | Phase 2 / Phase 3 | Completed | University Hospital, Lille | 40 | 2009-10-01 | 2026-05-14 |
| Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients Deferiprone - Iron Overload | Phase 3 | Completed | ApoPharma | 100 | 2007-08-01 | 2009-09-02 |
| Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients Deferiprone (L1), Desferrioxamine - Hemochromatosis | Phase 3 | Completed | Lipomed | 95 | 2002-01-01 | 2012-11-19 |
beta-Thalassemia (4) · Iron Overload (2) · Pantothenate Kinase-Associated Neurodegeneration (2) · Acute Kidney Injury (1) · Amyotrophic Lateral Sclerosis (1) · Anemia, Sickle Cell (1) · Diabetes Mellitus (1) · Hearing Loss, Sensorineural (1) · Hemochromatosis (1) · Iron Metabolism Disorders (1) · Optic Atrophy (1) · Parkinson Disease (1) · Peptic Ulcer (1) · Thalassemia (1)
Ain Shams University (3) · ApoPharma (3) · University Hospital, Lille (2) · Consorzio per Valutazioni Biologiche e Farmacologiche (1) · CorMedix Therapeutics (1) · Hadassah Medical Organization (1) · Lipomed (1)
Egypt (6) · Italy (3) · United Kingdom (3) · France (2) · Germany (2) · United States (2) · Albania (1) · Cyprus (1) · Greece (1) · Indonesia (1) · Israel (1) · Malaysia (1) · Tunisia (1) · Turkey (Türkiye) (1)
Elliott Vichinsky, MD (2) · Thomas Klopstock, MD (2) · Amal M El-Beshlawy, Prof. Dr. (1) · Aurelio Maggio, MD (1) · David Devos, MD, PhD (1) · David Devos, MD,PhD (1) · David Zangen, Professor (1) · Donato Bonifazi, Dr (1) · Fernando Tricta, MD (1) · Mohsen S Elalfy, professour (1) · Mohsen S. Elalfy, professour (1) · Nardo Nardocci, MD (1) · Patrick Chinnery, MD (1) · Prof. Mohsen S El Alfy, MD (1)
PMID 18055982, PMID 18351337, PMID 20921906, PMID 22180427, PMID 24251381, PMID 25600572, PMID 25943368, PMID 29119631, PMID 31202468, PMID 32470438, PMID 33926431, PMID 37975597, PMID 37975798
2008 (1), 2017 (1)